JAN 25, 2018 07:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
WEBINAR: Real World Utility of Fecal Calprotectin Testing
SPONSORED BY: Inova Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
4 12 629

Speakers:
  • Associate Professor and Co-Director, Stanford Children's Inflammatory Bowel Disease Center, Stanford University School of Medicine
    Biography
      Dr. Park is an Associate Professor in the Division of Gastroenterology, Department of Pediatrics, and a Stanford Health Policy faculty associate. He serves as the Co-Director of Stanford Children's IBD Center and the medical director of the Short Stay Infusion Unit at Stanford Children's Health. Dr. Park's current NIH-funded research is to discover cost-effective ways to manage Crohn's disease and ulcerative colitis. Recently, he has dedicated his clinical practice and research endeavors to monitor intestinal inflammation in patients with IBS and IBD.

    Abstract:

    DATE: January 25, 2018
    TIME: 07:00am PST, 10:00am EST, 4:00pm CET

     

    Patients presenting with persistent abdominal pain and diarrhea are common in clinical practice. Evaluation of these patients, assuming no alarm symptoms, can be difficult.  Inflammatory bowel disease is always a possibility and while few will actually have IBD, the symptoms of IBS and IBD can overlap.   Concern with a missed diagnosis of IBD leads many clinicians to request endoscopic evaluation. The strategy of testing for fecal calprotectin, a calcium and zinc binding protein complex found in neutrophil cytosolic protein, utilizes non-invasive diagnostic testing to stratify patients in need of endoscopic confirmation, reducing costs and improving the overall patient healthcare experience.  Additionally, studies have shown that fecal calprotectin testing is an effective tool for disease management to ascertain therapy response and predict IBD relapse.  Decreasing fecal calprotectin levels correlate well to drug effectiveness, while increasing levels can predict relapse even before the patient experiences clinical symptoms.  For all these reasons fecal calprotectin is an important biomarker for IBD diagnosis and disease management.

    Learning Objectives:

    • Utility of fecal calprotectin testing in diagnosis and IBD management. 
    • Correlating calprotectin cutoff levels with disease remission and predicting relapse.
    • Optimal frequency of measuring calprotectin; single vs repeat measures.

    Show Resources
    Loading Comments...